| INTRODUCTION
Patients chronically infected by the hepatitis C virus (HCV) are at risk of developing major liver complications. 1 Up to two-thirds of HCV-infected patients also experienced extrahepatic manifestations that include HCV-related autoimmune and/or lymphoproliferative disorders, and cardiovascular, renal, metabolic and central nervous system diseases. [2] [3] [4] [5] [6] [7] The link between extrahepatic manifestations
and HCV infection has been demonstrated for many years for lymphoproliferative disorders (mixed cryoglobulinemia, lymphoma), whereas it became more recently evident for cardiovascular, renal and metabolic diseases. 4, 5 Nevertheless, HCV infection showed higher morbidity and mortality rates for extra-hepatic complications, while viral eradication reduced the rate of extra-hepatic complications and deaths. 3, 5 New oral, interferon-free direct-acting anti-virals (DAA) offer opportunities to cure most patients. 1 Sofosbuvir plus ledipasvir has been shown to improve patient-reported outcomes after achieving sustained virological response (SVR). [8] [9] [10] As new all-oral interferonfree DAA regimens for HCV are approved, their effectiveness in a real-world setting and their economic impact on health systems and society require further assessment. Previous analyses have typically focused on the hepatic complications of HCV infection and have not considered the burden of extra-hepatic manifestations. 8, 11 There is a need to accurately characterise the burden of extrahepatic manifestations in HCV-infected patients, and the impact of achieving a SVR on the costs of managing these manifestations outside the United
States. 12 The objective of this study was to estimate the annual direct medical costs associated with the extrahepatic manifestations of HCV infection in France. Two estimates of total cost were calculated by using the 2 approaches to calculation of excess prevalence of extrahepatic manifestations in HCV patients in France described previously. Estimates of the impact of achieving SVR on the total costs of managing extrahepatic manifestations were obtained using the results of a metaanalysis 12 applied to the French healthcare costs. We estimated the total cost reduction according to SVR for 5 major extrahepatic manifestations for which data were available in the literature ie, mixed cryoglobulinemia vasculitis, end-stage renal disease, type 2 diabetes, stroke and myocardial infarction. [16] [17] [18] [19] [20] [21] [22] Results were weighted according to the study size population.
| ME TH ODS

| RESULTS
Among 134 HCV-infected patients seen in a specialised centre in 2015, prevalence rates of extrahepatic manifestations compared to the general population were particularly increased for mixed cryoglobulinemia vasculitis (51.5% vs 1.5%), rheumatoid-like arthritis (47.8% vs 0.1%), lymphoma (14.2% vs 0.24%), Sj€ ogren-like syndrome (6.0% vs 0.7%), cardiovascular diseases (ie, stroke and myocardial infarction, 6.8% vs 0.32% and 2.2% vs 0.29% respectively), type 2 diabetes (15.7% vs 9.3%) and depression (29.9% vs 17.2%) ( Table 1) .
Annual costs associated with the HCV-extrahepatic manifestations among the patients treated in this centre in France are detailed in Table 2 . Annual total medical costs were highest for lymphoma, followed by mixed cryoglobulinemia vasculitis, depression, stroke, Sj€ ogren-like syndrome, type 2 diabetes and heart diseases ( Table 3) .
The weighted average per-patient-per-year cost of these manifesta- Based on the assumption that all HCV patients receiving DAA would achieve a SVR, the total reduction in costs of managing extrahepatic manifestations in France was estimated to be 13.9 million € for type 2 diabetes, 8.6 million € for mixed cryoglobulinemia vasculitis, 6.7 million € for myocardial infarction, 2.4 million € for end-stage renal disease and 1.4 million € for stroke (Table 5 ).
| DISCUSSION
The European Association for the Study of the Liver (EASL) recommends that patients with significant extrahepatic manifestations of HCV infection should be prioritised for access to DAAs. 23, 24 The principal findings from the present study are, firstly, that the prevalence rates of a large number of comorbidities in patients with HCV infection in a specialised centre in France exceed the rates in the general population.
The excess prevalence of these extrahepatic manifestations translates to significantly increased annual direct medical costs. Secondly, by applying excess prevalence rates of extrahepatic manifestations in 
HCV-infected patients to the total population of HCV patients in
France, the economic burden amounts to approximately 215 million € per year. Finally, by making the assumption that all HCV patients receiving DAA treatment will achieve SVR, we have illustrated the potential for very substantial cost reductions associated with the management of extrahepatic manifestations in France.
Health spending in France has been estimated at 191 billion €, of which the costs of managing the hepatic complications of HCV infection contributes a sizable part. 25 In a retrospective hospital database analysis, 26 22 056 hospital stays were considered to be directly related to liver complications of HCV infection with a total cost estimated to be 61 million €. By contrast, we have estimated 27 Achieving SVR has been shown to reduce rates of extra-hepatic deaths. 28 Improved anti-viral efficacy of HCV drugs in the DAA era led to increased clinical effectiveness on cryoglobulinemia vasculitis manifestations and a lower death rate. 29 The use of DAAs was associated with higher costs for HCV drugs, while costs related to both hospitalisations and non-anti-viral treatments decreased. Costs of medical care related to another non-HCV-related vasculitis were estimated to be between 24 000 and 61 000 US$ per year. 30 The immunosuppressant therapy was given for many years, whereas in HCV-cryoglobulinemia vasculitis, effective anti-viral therapy usually leads to the final cure of viral disease and vasculitis as well.
We acknowledge some limitations to this study. For obvious reasons, only a limited number of the many suggested extrahepatic manifestations have been considered in this study. Long-term indirect cost of some invalidating extrahepatic manifestations such as peripheral neuropathy, fatigue and cognitive dysfunction are difficult to estimate. This may have led to underestimation of the related costs. Patients were followed in a unique specialised tertiary centre that could reflect rates of HCV-extrahepatic manifestations that are not completely generalisable. However, the prevalence rates of other extrahepatic manifestations were very similar to those previously reported. 4, 6, 7 Increased annual costs related to the care of HCVextrahepatic manifestations should be also analysed in line with higher mortality rate for extra-hepatic complications. 31 Another limitation was the low numbers of studies with available data used to estimate the total French cost reduction of HCV-extrahepatic manifestations associated with SVR.
In summary, extrahepatic manifestations of HCV infection are frequent, costly and substantially add to the overall economic burden of HCV infection in France. Sustained virological response after antiviral therapy should have a good impact on total cost reduction.
